Author(s):
Pathan Amanulla Khan, Mahadevamma Lingaiah
Email(s):
mahadevammalingaiah11@gmail.com
DOI:
10.52711/0974-360X.2025.00831 
Address:
Pathan Amanulla Khan1, Mahadevamma Lingaiah2*
1 Research Scholar, Dept. of Pharmacy Practice, College of Pharmaceutical Sciences, School of Health Sciences, DSU, Harohalli, Bangalore.
2Associate Prof., Dept. of Pharmacy Practice, College of Pharmaceutical Sciences, School of Health Sciences, DSU, Harohalli, Bangalore.
*Corresponding Author
Published In:
Volume - 18,
Issue - 12,
Year - 2025
ABSTRACT:
HIV is a retrovirus that selectively targets CD4+ T cells and HIV infection is prevalent on a global scale. The treatment involves HAART therapy. The appropriate use of HAART significantly reduces HIV replication. TLD is one such HAART regimen that contains Dolutegravir (DTG) as a preferred first-line treatment for HIV, comprising two NRTIs (TDF 300 mg, 3TC 300 mg) and one INSTI (DTG 50 mg) in a fixed- dose combination. This regimen effectively suppresses plasma HIV RNA load to undetectable levels, restores CD4+ cell counts, and offers improved tolerability and drug-resistance barriers compared to older Integrase inhibitors & NRTIs. Methods: The present Ambispective study compared the efficacy of the TLD regimen in 1021 patients ageing (19-75 years) living with HIV-1. Data was collected prospectively through follow-up visits and retrospectively through medical records. Objectives: Objectives were comparing immunologic response (CD4 cell count change), virologic response (viral load reduction), in association with Medication adherence, Results: Of the 1021 PLWH, 51.3% were males, 46.5% were females while 2.2% were transgender. The study demonstrated good CD4 count elevation at 6, 12 and 24 months of TLD regimen initiation while the viral load had marked suppression to <1000 c/ml after 36 to 48 months of treatment. Conclusion: Study makes a significant increase in CD4+ T cell count with an achievement of undetectable viral load levels over time. This highlights the regimen's potential for HIV infection management with significant contribution to the optimization of HIV treatment outcomes, enhancing patient quality of life, and advancing progress towards achieving the desired goals for HIV control.
Cite this article:
Pathan Amanulla Khan, Mahadevamma Lingaiah. Efficacy of Tenofovir Disoproxil-Lamivudine-Dolutegravir regimen in treatment of South Indian Adult Patients Living with HIV-1. Research Journal Pharmacy and Technology. 2025;18(12):5763-8. doi: 10.52711/0974-360X.2025.00831
Cite(Electronic):
Pathan Amanulla Khan, Mahadevamma Lingaiah. Efficacy of Tenofovir Disoproxil-Lamivudine-Dolutegravir regimen in treatment of South Indian Adult Patients Living with HIV-1. Research Journal Pharmacy and Technology. 2025;18(12):5763-8. doi: 10.52711/0974-360X.2025.00831 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-12-21
REFERENCES:
1. Ranjita Behera. HIV/AIDS Among Displaced Women. Asian Journal of Management. 2018; 9(1):529-530.
2. Juliet Sylvia, Basavanthappa, Richard. A Study to Compare and Correlate the Knowledge and Attitude Regarding HIV/AIDS among Young Married and Unmarried Women in Selected Urban Slums of Madurai, Tamil Nadu. Asian J. Nur. Edu. and Research. 2012; 2(3): 118-125.
3. C. U. Nwozichi, A.A. Farotimi. Knowledge and Acceptance of HIV Counselling and Testing (HCT) among Non-Teaching Staff of a Private University in South-West Nigeria: The Case of Babcock University. Asian J. Nur. Edu. and Research. 2014; 4(3): 352-356.
4. Patel Mihirkumar Maheshbhai. A Study to assess the quality of life of Aids patients admitted in Civil Hospital, Mehsana. Asian J. Nur. Edu. and Research. 2015; 5(4): 461-462.
5. Korencak M, Byrne M, Richter E, Schultz BT, Juszczak P, Ake JA, Ganesan A, Okulicz JF, Robb ML, de Los Reyes B, Winning S, Fandrey J, Burgess TH, Esser S, Michael NL, Agan BK, Streeck H. Effect of HIV infection and antiretroviral therapy on immune cellular functions. JCI Insight. 2019 Jun 20; 4(12): e126675.doi: 10.1172/jci.insight.126675.
6. Shu W, Du F, Bai JS, Yin LY, Duan KW, Li CW. A Real-world Evidence-based Management of HIV by Differential Duration HAART Treatment and its Association with Incidence of Oral Lesions. Curr HIV Res. 2022; 20(1): 91-99. doi: 10.2174/1570162X20666211227154558.
7. Manthankumar N. Kapadiya. Aids Case Study. International Journal of Nursing Education and Research. 2022; 10(1): 21-2.
8. Hathoikim Misao, Ibaiasuk Lamare, Mecievinü Rhetso, Nihali Devi Rana, Phibadashisha Chyne, Y Zuchanbeni Humtsoe. Knowledge and attitude towards HIV/AIDS among undergraduate students. Asian J. Nursing Education and Research. 2020; 10(2): 189-193.
9. Threats M, Brawner BM, Montgomery TM, Abrams J, Jemmott LS, Crouch PC, Freeborn K, Kamitani E, Enah C. A Review of Recent HIV Prevention Interventions and Future Considerations for Nursing Science. J Assoc Nurses AIDS Care. 2021 May-Jun 01; 32(3): 373-391. doi: 10.1097/JNC.0000000000000246.
10. Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, Ripin D, Flexner C, Domanico PL. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. 2018 Jul 31; 32(12): 1551-1561. doi: 10.1097/QAD.0000000000001845.
11. Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks of clinical obesity? J Virus Erad. 2019 Jan 1; 5(1): 41-43. doi: 10.1016/S2055-6640(20)30277-6.
12. Yang J, Wei G, Gui F, Zhao Y, Chen T, Tan J. Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer. AIDS Res Ther. 2022 Sep 23;19(1): 45. doi: 10.1186/s12981-022-00470-3.
13. Madhu A, Shivalinge Gowda KP, Manjula B. Novel Therapies to Combat HIV: A Review. Research J. Pharmacology and Pharmacodynamics 2009; 1(1):01-06.
14. Smith SJ, Zhao XZ, Passos DO, Lyumkis D, Burke TR Jr, Hughes SH. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs. Viruses. 2021 Jan 29;13(2): 205. doi: 10.3390/v13020205.
15. Zhao AV, Crutchley RD, Guduru RC, Ton K, Lam T, Min AC. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. Retrovirology. 2022 Oct 22; 19(1): 22. doi: 10.1186/s12977-022-00608-1.
16. Scarsi KK, Havens JP, Podany AT, Avedissian SN, Fletcher CV. HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety. Drugs. 2020 Nov; 80(16): 1649-1676. doi: 10.1007/s40265-020-01379-9.
17. Bhavimani Guru, Nitin M. Pharmacological Studies on Drug-Drug Interactions between Antidiabetic Drug (Glibenclamide) and Selective Anti-HIV Drug (Lamivudine) in Rats and Rabbits. Res. J. Pharmacology and Pharmacodynamics. 2017; 9(3): 117-121.
18. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S; extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96-week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013 Nov; 13(11): 927-35. doi: 10.1016/S1473-3099(13)70257-3.
19. Raffi F, Rachlis A, Brinson C, Arasteh K, Gó Rgolas M, Brennan C, Pappa K, Almond S, Granier C, Nichols WG, Cuffe RL, Eron J, Walmsley S. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS 2015; 29: 167-174.
20. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, SaagM, Harris J, Brennan C, Fujiwara T, Min S; ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1infection (FLAMINGO): 48-week results from the randomised openlabel phase 3 b study. Lancet. 2014; 383: 2222-2231.
21. De Boer MGJ, Van Den Berk GEL, Van Holten N, Oryszcyn JE, Dorama W, Ait Moha D, Brinkman K, To C. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 2016; 30: 2831-2834.
22. Dravid A, Morkar D, Prasad D, Ramapuram JT, Patel KV, Naik KS, Bhrusundi M, Kulkarni M, Hegde S, Anuradha S, Nageswaramma S, Madan S, Jayaprakash T, Kulkarni V. A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1. Pragmat Obs Res. 2022 Aug 10; 13:75-84. doi: 10.2147/POR.S361907.
23. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S; SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48-week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013 Mar 2; 381(9868): 735-43. doi: 10.1016/S0140-6736(12)61853-4.
24. Hurbans N, Naidoo P. Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study. BMC Infect Dis. 2024 Mar 21; 24(1):343. doi: 10.1186/s12879-024-09202-6.
25. Rossetti B, Baldin G, Sterrantino G, Rusconi S, De Vito A, Giacometti A, Gagliardini R, Colafigli M, Capetti A, d'Ettorre G, Celani L, Lagi F, Ciccullo A, De Luca A, Di Giambenedetto S, Madeddu G. Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study. Antiviral Res. 2019 Sep; 169: 104552. doi: 10.1016/j.antiviral.2019.104552.
26. Moosa A, Gengiah TN, Lewis L, Naidoo K. Long-term adherence to antiretrovi¬ral therapy in a South African adult patient cohort: a retrospective study. BMC Infect Dis. 2019; 19(1): 1–12.
27. C. Rajeswari, Sugavana Selvi, Ramachandra. Anti-Retro Viral Therapy (ART) Adherence and Factors affecting Adherence among People living with HIV (PLHIVs). Asian J. Nur. Edu. and Research. 2017; 7(3): 337-340.
28. Ganesh Lal Patidar. A Study to Assess the Factors Affecting Compliance of ART among HIV Patients at selected ART centers of Pune City. Int. J. Nur. Edu. and Research. 2017; 5(3): 338-340.
29. Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. E Clinical Medicine. 2020; 28: 2589–5370.
30. Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren JD, De Luca A, Pillay D, Mellors J, Cambiano V, Bansi-Matharu L, Nakagawa F, Kalua T, Jahn A, Apollo T, Mugurungi O, Clayden P, Gupta RK, Barnabas R, Revill P, Cohn J, Bertagnolio S, Calmy A. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV. 2019 Feb; 6(2): e116-e127. doi: 10.1016/S2352-3018(18)30317-5.